Close Menu

NEW YORK – The US Food and Drug Administration announced Thursday that Cepheid's test for SARS-CoV-2, influenza, and respiratory syncytial virus received Emergency Use Authorization for use in high and moderate complexity laboratories and at the point of care. 

The rapid multiplex RT-PCR test detects and differentiates SARS-CoV-2, influenza A and B, and respiratory syncytial virus RNA and can provide results in 35 minutes. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that US states and territories are seeking more funding for the distribution of SARS-CoV-2 vaccines.

The strain now accounts for about 80 percent of cases in Wales and Scotland, and about half of cases in England, the Guardian reports.

A new study suggests that using CRISPR to edit human embryonic DNA can lead to the loss of whole chromosomes, as the Associated Press reports.

In Science this week: ancient dog genomes highlight long ties with humans, genomic analysis of 40,000-year-old early East Asian individual, and more.